# K141532

# 510(k) SUMMARY

1. Date:

July 11, 2014

2 Submitter:

Guangzhou Wondfo Biotech Co., Ltd. No.8 Lizhishan Road, Science City, Luogang District, Guangzhou, P.R. China 510663

3. Contact person:

Joe Shia   
LSI International Inc.   
504 East Diamond Ave., Suite F Gaithersburg, MD 20878   
Telephone: 240-505-7880   
Fax: 301-916-6213   
Email:shiajl@yahoo.com

Device Name:

$\mathsf { C R } ^ { 3 }$ Keyless Split Sample Cup Amphetamine-Cocaine

Classification:

Product Code CFR # DKZ 21CFR 862.3100 DIO 21CFR 862.3250

Predicate Devices:

k130665 Wondfo Multi-Drug Urine Test Cup Wondfo Multi-Drug Urine Test Panel

6Intended Use

CR3 Keyless Split Sample Cup Amphetamine-Cocaine is a rapid test for the qualitative detection of d-Amphetamine (major metabolite of Amphetamine) and Benzoylecgonine (major metabolite of Cocaine) in human urine at a cutoff concentration of $\scriptstyle 1 0 0 0 { \mathrm { n g / m L } }$ and $3 0 0 \mathrm { n g / m L }$ , respectively.

The test provides only preliminary test results. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. GC/MS is the preferred confirmatory method. Clinical consideration and professional judgment should be exercised with any drug of abuse test result, particularly when the preliminary result is positive.

For in vitro diagnostic use only. It is intended for over-the-counter and for prescription use.

The CR3 Keyless Split Sample Cup Amphetamine-Cocaine test uses immunochromatographic assays for amphetamine and cocaine. The test is a lateral flow, one step system for the qualitative detection of d-Amphetamine (major metabolite of Amphetamine) and Benzoylecgonine (major metabolite of Cocaine) in human urine.

# 8. Substantial Equivalence Information

<table><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device ÷</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Indication(s)for use</td><td rowspan=1 colspan=1>For the qualitative determination ofAmphetamine and Cocaine inhuman urine</td><td rowspan=1 colspan=1>Same, but alsodetects other drugs inhuman urine</td></tr><tr><td rowspan=1 colspan=1>Methodology</td><td rowspan=1 colspan=1>Competitive binding, lateral flowimmunochromatographic assaysbased on the principle of antigenantibody immunochemistry.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Results</td><td rowspan=1 colspan=1>Qualitative</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>SpecimenType</td><td rowspan=1 colspan=1>Human urine</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Cut Off Values</td><td rowspan=1 colspan=1>Amphetamine: 1000ng/mlCocaine: 300ng/ml</td><td rowspan=1 colspan=1>Same forAmphetamine andCocaine</td></tr><tr><td rowspan=1 colspan=1>Configurations</td><td rowspan=1 colspan=1>Cup</td><td rowspan=1 colspan=1>Cup, Panel</td></tr><tr><td rowspan=1 colspan=1>Conditions forUse</td><td rowspan=1 colspan=1>Over-the-Counter &amp; PrescriptionUse</td><td rowspan=1 colspan=1>Same</td></tr></table>

# Test Principle

The CR3 Keyless Split Sample Cup Amphetamine-Cocaine test is a rapid test for the qualitative detection of d-Amphetamine and benzoylecgonine in urine samples and contains lateral flow chromatographic immunoassays for amphetamine and cocaine. Each assay uses a mouse monoclonal anti-drug antibody-dye conjugate, fixed drug-protein conjugates, and anti-mouse IgG polyclonal antibodies coated on the test membranes. When the absorbent end of the test is immersed into a urine sample, the urine is absorbed into the device by capillary action and mixes with the antibody-dye conjugate, flowing across the pre-coated membrane. At analyte concentrations below the target cut-off, antibody-dye conjugates bind to the drug-protein conjugate immobilized in the Test Region (T) of the device. This produces a colored test line that indicates a negative result. When analyte concentration is above the cut-off, analyte molecules bind to the antibody-dye conjugate, preventing the antibody-dye conjugate from binding to the drug-protein conjugate immobilized in the Test Region (T) of the device. No colored band shows in the test region, indicating a potentially positive result. A band should form in the control region (C) of the device regardless of the presence of drug or metabolite in the sample.

10. Performance Characteristics

1. Analytical Performance

a. Precision Precision studies were carried out for samples with concentrations of- $. 1 0 0 \%$ cut-off, $- 7 5 \%$ cut-off, $- 5 0 \%$ cut-off, $- 2 5 \%$ cut-off, at the cut-off, $+ 2 5 \%$ cut-off, $45 0 \%$ cut-off, $+ 7 5 \%$ cut-off and $+ 1 0 0 \%$ cut-off. For each concentration, tests were performed two runs per day for 25 days. All sample aliquots were masked and randomized. The results obtained are summarized in the following tables:

A. For Amphetamine (AMP) testing   

<table><tr><td rowspan=1 colspan=1>ResultAMP</td><td rowspan=1 colspan=1>-100%cut-off</td><td rowspan=1 colspan=1>-75%cut-off</td><td rowspan=1 colspan=1>-50%cut-off</td><td rowspan=1 colspan=1>-25%cut-off</td><td rowspan=1 colspan=1>cut-off</td><td rowspan=1 colspan=1>+25%cut-off</td><td rowspan=1 colspan=1>+50%cut-off</td><td rowspan=1 colspan=1>+75%cut-off</td><td rowspan=1 colspan=1>+100%cut-off</td></tr><tr><td rowspan=1 colspan=1>W11710501CU5</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>42+/8-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr><tr><td rowspan=1 colspan=1>W11710502CU5</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>43+/7-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr><tr><td rowspan=1 colspan=1>W11710503CU5</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>43+/7-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr></table>

B. For Cocaine (COC) testing   

<table><tr><td rowspan=1 colspan=1>ResultCOC</td><td rowspan=1 colspan=1>-100%cut-off</td><td rowspan=1 colspan=1>-75%cut-off</td><td rowspan=1 colspan=1>-50%cut- off</td><td rowspan=1 colspan=1>-25%cut-off</td><td rowspan=1 colspan=1>cut-off</td><td rowspan=1 colspan=1>+25%cut-off</td><td rowspan=1 colspan=1>+50%cut-off</td><td rowspan=1 colspan=1>&#x27;+75%cut-off</td><td rowspan=1 colspan=1>+100%cut-off</td></tr><tr><td rowspan=1 colspan=1>W11710501CU5</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>41+/9-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr><tr><td rowspan=1 colspan=1>W11710502CU5</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>43+/7-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr><tr><td rowspan=1 colspan=1>W11710503CU5</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>42+/8-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr></table>

b. Linearity Not applicable.

c. Stability The CR3 Keyless Split Sample Cup Amphetamine-Cocaine is stable at $4 { - } 3 0 ^ { \circ } \mathrm { C }$ EY for 18 months as determined by conducting accelerated and real-time stability testing.

Control materials are not provided with the device. The labeling provides information on how to obtain control materials.

d. Cut-off

A total of 125 amphetamine samples and 125 cocaine samples equally distributed at concentrations of- $5 0 \%$ $- 2 5 \% ,$ at the cut-off, $+ 2 5 \%$ , $+ 5 0 \%$ of their respective cut-offs were labeled by a person who prepared them and would not participate in the sample testing. These samples were tested using three different lots by three different operators. Results were all positive at $+ 2 5 \%$ and $+ 5 0 \%$ cut-off and all negative at $- 2 5 \%$ and $- 5 0 \%$ cut-off for both cocaine and amphetamine. The following cut-off values for the test devices have been verified.

<table><tr><td rowspan=1 colspan=1>Test</td><td rowspan=1 colspan=1>Calibrator</td><td rowspan=1 colspan=1>Cut-off (ng/ml)</td></tr><tr><td rowspan=1 colspan=1>Amphetamine(AMP)</td><td rowspan=1 colspan=1>d-Amphetamine</td><td rowspan=1 colspan=1>1000</td></tr><tr><td rowspan=1 colspan=1>Cocaine(COC)</td><td rowspan=1 colspan=1>Benzoylecgonine</td><td rowspan=1 colspan=1>300</td></tr></table>

e. Interference

Potential interfering substances found in human urine of physiological or pathological conditions were added to drug-free urine and to urine containing target drugs (d-amphetamine or benzoylecgonine) at $25 \%$ below and $2 5 \%$ above the cut-off. These urine samples were tested using three batches of the CR3Keyless Split Sample Cup Amphetamine-Cocaine by three different operators. Compounds that showed no interference at a concentration of $1 0 0 \mu \mathrm { g / m L }$ are summarized below:

# d-Amphetamine

4-Acetamidophenol   
Acetophenetidin   
N-Acetylprocainamid   
Acetylsalicylic acid   
Aminopyrine   
Amitryptyline   
Amobarbital   
Amoxicillin   
Ampicillin   
Ascorbic acid   
Apomorphine   
Aspartame   
Atropine   
Benzilic acid   
Benzoic acid   
Benzoylecgonine   
Bilirubin   
Brompheniramine   
Caffeine   
Cannabidiol   
(-) Y Ephedrine   
Erythromycin   
$\beta$ -Estradiol   
Estrone-3-sulfate   
Ethyl-p-aminobenzoate   
Fenfluramine   
Fenoprofen   
Furosemide   
Gentisic acid   
Hemoglobin   
Hydralazine   
Hydrochlorothiazide   
Hydrocodone   
Hydrocortisone   
O-Hydroxyhippuric acid   
3-Hydroxytyramine   
Ibuprofen   
Imipramine   
(-) Isoproterenol   
Isoxsuprine   
Penicillin-G   
Pentazocaine   
Pentobarbital   
Perphenazine   
Phencyclidine   
Phenelzine   
Phendimetrazine   
Phenobarbital   
Phetoin   
L-Phenylephrine   
$\beta$ -Phenylethlamine   
Phenylpropanolamine   
Prednisolone   
Prednisone   
Procaine   
Promazine   
Promethazine   
D,L-Propanolol   
Propiomazine   
D-Propoxyphene   
Cannabinol   
Chloralhydrate   
Chloramphenicol   
Chlordiazepoxide   
Chlorothiazide   
$( \pm )$ Chlorpheniramine   
Chlorpromazine   
Chlorquine   
Cholesterol   
Clomipramine   
Clonidine   
Cocaine hydrochloride   
Codeine   
Cortisone   
(-) Cotinine   
Creatinine   
Deoxycorticosterone   
Dextromethorphan   
Diazepam   
Diclofenac   
Diflunisal   
Digoxin   
Diphenhydramine   
Doxylamine   
Ecgonine   
hydrochloride   
Ecgonine methylester   
(IR,2S)-(-)-Ephedrine   
L-Ephedrine   
Ketamine   
Ketoprofen   
Labetalol   
Levorphanol   
Loperamide   
Maprotiline   
Meperidine   
Meprobamate   
Methadone   
Methylphenidate   
Morphine-3-Dglucuronide   
Nalidixic acid   
Naloxone   
Naltrexone   
Naproxen   
Niacinamide   
Nifedipine   
Norcodein   
Norethindrone   
D-Norpropoxyphene   
Noscapine   
D,L-Octopamine   
Oxalic acid   
Oxazepam   
Oxolinic acid   
Oxycodone   
Oxymetazoline   
Papaverine   
Quinidine   
Quinine   
Ranitidine   
Salicylic acid   
Secobarbital   
Serotonin   
Sulfamethazine   
Sulindac   
Temazepam   
Tetracycline   
Tetrahydrocortisone   
Tetrahydrozoline   
49-THC-COOH   
Thebaine   
Thiamine   
Thioridazine   
D,L-Thyroxine   
Tolbutamine   
Triamterene   
Trifluoperazine   
Trimethoprim   
Trimipramine   
Tryptamine   
D, L-Tyrosine   
Uric acid

Verapamil Zomepirac

# Benzoylecgonine

Acetominophen   
Acetophenetidin   
N-Acetylprocainamide   
Acetylsalicylic acid   
Aminopyrine   
Amitryptyline   
Amobarbital   
Amoxicillin   
Ampicillin   
L-Ascorbic acid   
DL-Amphetamine Sulfate   
Apomorphine   
Aspartame   
Atropine   
Benzilic acid   
Estrone-3-sulfate   
Ethyl-p-aminobenzoate   
Fenoprofen   
Furosemide   
Gentisic acid   
Hemoglobin   
Hydralazine   
Hydrochlorothiazide   
Hydrocodone   
Hydrocortisone   
O-Hydroxyhippuric acid   
p-Hydroxymethamphetamine   
3-Hydroxytyramine   
Ibuprofen   
Imipramine   
Papaverine   
Penicillin-G   
Pentobarbital   
Perphenazine   
Phencyclidine   
Phenelzine   
Phenobarbital   
Phentermine   
L-Phenylephrine   
$\beta$ Phenylethylamine   
Phenylpropanolamine   
Prednisolone   
Prednisone   
Procaine   
Promazine   
Benzoic acid   
Benzphetamine   
Bilirubin   
$( \pm )$ -Brompheniramine   
Caffeine   
Cannabidiol   
Cannabinol   
Chloralhydrate   
Chloramphenicol   
Chlordiazepoxide   
Chlorothiazide   
$( \pm )$ -Chlorpheniramine   
Chlorpromazine   
Iproniazid   
$( \pm )$ - Isoproterenol   
Isoxsuprine   
Ketamine   
Ketoprofen   
Labetalol   
Levorphanol   
Loperamide   
Maprotiline   
Meperidine   
Meprobamate   
Methadone   
Methoxyphenamine

Chlorquine

() -3,4-Methylene. dioxyamphetamine hydrochloride   
(±)-3.4-Methylenedioxymethamphetamine hydrochloride

Cholesterol

Morphine-3 $\beta$ D glucuronide

Promethazine   
DL-Propranolol   
D-Propoxyphene   
D-Pseudoephedrine   
Quinidine   
Quinine   
Ranitidine   
Salicylic acid   
Secobarbital   
Serotonin   
Sulfamethazine   
Sulindac   
Temazepam   
Tetracycline   
Tetrahydrocortisone, cetate   
Tetrahydrocortisone 3-(β-D glucuronide   
Tetrahydrozoline   
Thebaine   
Thiamine   
Thioridazine   
DL-Tyrosine   
Tolbutamide   
Triamterene   
Trifluoperazine   
Trimethoprim   
Trimipramine   
Tryptamine   
DL-Tryptophan   
Tyramine   
Uric acid   
Verapamil   
Zomepirac   
Clomipramine   
Clonidine   
Codeine   
Cortisone   
(-) Cotinine   
Creatinine   
Deoxycorticosterone   
Dextromethorphan   
Diazepam   
Diclofenac   
Diflunisal   
Digoxin   
Diphenhydramine   
Doxylamine   
Ecgonine methylester   
$( - ) -Psi$ -Ephedrine   
Erythromycin   
$\beta .$ Estradiol   
Morphine Sulfate   
Nalidixic acid   
Naloxone   
Naltrexone   
Naproxen   
Niacinamide   
Nifedipine   
Norcodein   
Norethindrone   
D-Norpropoxyphene   
Noscapine   
DL-Octopamine   
Oxalic acid   
Oxazepam   
Oxolinic acid   
Oxycodone   
Oxymetazoline

f. Specificity

To test the specificity, drug metabolites and other components that are likely to be present in urine samples were tested. The target drug (d-Amphetamine or Benzoylecgonine), its drug metabolites and the related compounds were studied. These samples were tested using three batches of the CR3Keyless Split Sample Cup Amphetamine-Cocaine by three different operators. The drug metabolites and other components were tested at different concentrations. The obtained lowest detectable concentration was used to calculate the cross-reactivity. Results are shown in the following tables.

<table><tr><td rowspan=1 colspan=1>AMP (Amphetamine)(d-Amphetamine,Cut-off=1000 ng/mL)</td><td rowspan=1 colspan=1>Result</td><td rowspan=1 colspan=1>%Cross-Reactivity</td></tr><tr><td rowspan=1 colspan=1>d-Amphetamine</td><td rowspan=1 colspan=1>Positiveat 1,000ng/mL</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>1-Amphetamine</td><td rowspan=1 colspan=1>Positive at 50,000ng/mL</td><td rowspan=1 colspan=1>2%</td></tr><tr><td rowspan=1 colspan=1>d,l-Amphetamine</td><td rowspan=1 colspan=1>Positive at 3,000ng/mL</td><td rowspan=1 colspan=1>33%</td></tr><tr><td rowspan=1 colspan=1>(+/-) 3,4-methylenedioxyamphetamine(MDA)</td><td rowspan=1 colspan=1>Positive at 5,000ng/mL</td><td rowspan=1 colspan=1>20%</td></tr><tr><td rowspan=1 colspan=1>Phentermine</td><td rowspan=1 colspan=1>Positive at 3,000ng/mL</td><td rowspan=1 colspan=1>33%</td></tr><tr><td rowspan=1 colspan=1>d-Methamphetamine</td><td rowspan=1 colspan=1>&gt;100,000 ng/mL</td><td rowspan=1 colspan=1>&lt;1%</td></tr><tr><td rowspan=1 colspan=1>1-Methamphetamine</td><td rowspan=1 colspan=1>&gt;100,000 ng/mL</td><td rowspan=1 colspan=1>&lt;1%</td></tr><tr><td rowspan=1 colspan=1>Ephedrine</td><td rowspan=1 colspan=1>&gt;100,000 ng/mL</td><td rowspan=1 colspan=1>&lt;1%</td></tr><tr><td rowspan=1 colspan=1>3,4-Methylenedioxyethylamphetamine(MDEA)</td><td rowspan=1 colspan=1>&gt;100,000 ng/mL</td><td rowspan=1 colspan=1>&lt;1%</td></tr></table>

<table><tr><td rowspan=1 colspan=1>COC(Cocaine)(Benzoylecgonine,Cut-off=300 ng/mL)</td><td rowspan=1 colspan=1>Result</td><td rowspan=1 colspan=1>%Cross-Reactivity</td></tr><tr><td rowspan=1 colspan=1>Benzoylecgonine</td><td rowspan=1 colspan=1>Positive at 300 ng/mL</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Cocaine HCI</td><td rowspan=1 colspan=1>Positive at 750 ng/mL</td><td rowspan=1 colspan=1>40%</td></tr><tr><td rowspan=1 colspan=1>Cocaethylene</td><td rowspan=1 colspan=1>Positive at 12,500ng/mL</td><td rowspan=1 colspan=1>2.4%</td></tr><tr><td rowspan=1 colspan=1>Ecgonine</td><td rowspan=1 colspan=1>Positive at 32,000ng/mL</td><td rowspan=1 colspan=1>&lt;1%</td></tr></table>

# g. Effect of Urinary Density and pH

Twelve urine samples of normal, high, and low specific density ranges (1.000 to 1.035) were collected and spiked with either d-Amphetamine or benzoylecgonine at $2 5 \%$ below and $2 5 \%$ above the corresponding cut-off level. These samples were tested using three batches of the CR3Keyless Split Sample Cup Amphetamine-Cocaine by three different operators.

The $\mathsf { p H }$ of an aliquot negative urine pool was adjusted to pH ranges of 4.00 to 9.00 in $1 ~ { \mathfrak { p } } \mathrm { H }$ unit increments and spiked with d-Amphetamine or benzoylecgonine at $2 5 \%$ below and $2 5 \%$ above the corresponding cut-off levels. These samples were tested using three batches of the CR3Keyless Split Sample Cup Amphetamine-Cocaine by three different operators.

The device performance was found not affected by varying urine density and $\mathfrak { p H }$ .

2 Comparison Studies

The method comparison for the $\boldsymbol { \mathrm { C R } ^ { 3 } }$ Keyless Split Sample Cup Amphetamine-Cocaine was performed in-house with three laboratory assistants. Operators ran 80 (40 negative and 40 positive) unaltered clinical samples. The samples were masked and randomized. The obtained test results are compared to GC/MS results. The results are presented in the table below:

Amphetamine   

<table><tr><td rowspan=1 colspan=1>GroupOperators</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>LowNegative byGC/MS(less than-50%)</td><td rowspan=1 colspan=1>Near CutoffNegative byGC/MS(Between-50% andcutoff</td><td rowspan=1 colspan=1>Near CutoffPositive byGC/MS(Betweenthe cutoffand +50%)</td><td rowspan=1 colspan=1>HighPositive byGC/MS(greaterthan +50%)</td></tr><tr><td rowspan=2 colspan=1>Viewer A</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>Viewer B</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>Viewer C</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td></tr></table>

Discordant table:   

<table><tr><td colspan="1" rowspan="1">Viewer</td><td colspan="1" rowspan="1">Sample number</td><td colspan="1" rowspan="1">GC/MS result</td><td colspan="1" rowspan="1">Viewer result</td></tr><tr><td colspan="1" rowspan="1">Viewer A</td><td colspan="1" rowspan="1">AMPC1035</td><td colspan="1" rowspan="1">811</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer A</td><td colspan="1" rowspan="1">AMPC1062</td><td colspan="1" rowspan="1">945</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer A</td><td colspan="1" rowspan="1">AMPC1065</td><td colspan="1" rowspan="1">987</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer A</td><td colspan="1" rowspan="1">AMPC1061</td><td colspan="1" rowspan="1">1033</td><td colspan="1" rowspan="1">negative</td></tr><tr><td colspan="1" rowspan="1">Viewer A</td><td colspan="1" rowspan="1">AMPC1063</td><td colspan="1" rowspan="1">1002</td><td colspan="1" rowspan="1">negative</td></tr><tr><td colspan="1" rowspan="1">Viewer A</td><td colspan="1" rowspan="1">AMPC1064</td><td colspan="1" rowspan="1">1014</td><td colspan="1" rowspan="1">negative</td></tr><tr><td colspan="1" rowspan="1">Viewer B</td><td colspan="1" rowspan="1">AMPC1032</td><td colspan="1" rowspan="1">781</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer B</td><td colspan="1" rowspan="1">AMPC1035</td><td colspan="1" rowspan="1">811</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer B</td><td colspan="1" rowspan="1">AMPC1062</td><td colspan="1" rowspan="1">945</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer B</td><td colspan="1" rowspan="1">AMPC1065</td><td colspan="1" rowspan="1">987</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer B</td><td colspan="1" rowspan="1">AMPC1061</td><td colspan="1" rowspan="1">1033</td><td colspan="1" rowspan="1">negative</td></tr><tr><td colspan="1" rowspan="1">Viewer B</td><td colspan="1" rowspan="1">AMPC1063</td><td colspan="1" rowspan="1">1002</td><td colspan="1" rowspan="1">negative</td></tr><tr><td colspan="1" rowspan="1">Viewer B</td><td colspan="1" rowspan="1">AMPC1064</td><td colspan="1" rowspan="1">1014</td><td colspan="1" rowspan="1">negative</td></tr><tr><td colspan="1" rowspan="1">Viewer B</td><td colspan="1" rowspan="1">AMPC1092</td><td colspan="1" rowspan="1">1185</td><td colspan="1" rowspan="1">negative</td></tr><tr><td colspan="1" rowspan="1">Viewer B</td><td colspan="1" rowspan="1">AMPC1094</td><td colspan="1" rowspan="1">1312</td><td colspan="1" rowspan="1">negative</td></tr><tr><td colspan="1" rowspan="1">Viewer C</td><td colspan="1" rowspan="1">AMPC1033</td><td colspan="1" rowspan="1">702</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer C</td><td colspan="1" rowspan="1">AMPC1035</td><td colspan="1" rowspan="1">811</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer C</td><td colspan="1" rowspan="1">AMPC1065</td><td colspan="1" rowspan="1">987</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer C</td><td colspan="1" rowspan="1">AMPC1061</td><td colspan="1" rowspan="1">1033</td><td colspan="1" rowspan="1">negative</td></tr><tr><td colspan="1" rowspan="1">Viewer C</td><td colspan="1" rowspan="1">AMPC1063</td><td colspan="1" rowspan="1">1002</td><td colspan="1" rowspan="1">negative</td></tr><tr><td colspan="1" rowspan="1">Viewer C</td><td colspan="1" rowspan="1">AMPC1091</td><td colspan="1" rowspan="1">1212</td><td colspan="1" rowspan="1">negative</td></tr><tr><td colspan="1" rowspan="1">Viewer C</td><td colspan="1" rowspan="1">AMPC1093</td><td colspan="1" rowspan="1">1296</td><td colspan="1" rowspan="1">negative</td></tr></table>

Cocaine   

<table><tr><td rowspan=1 colspan=1>GroupOperators</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>LowNegative byGC/MS(less than-50%)</td><td rowspan=1 colspan=1>Near CutoffNegative byGC/MS(Between-50% andcutoff)</td><td rowspan=1 colspan=1>Near CutoffPositive byGC/MS(Betweenthe cutoffand +50%)</td><td rowspan=1 colspan=1>HighPositive byGC/MS(greaterthan +50%)</td></tr><tr><td rowspan=2 colspan=1>Viewer A</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>Viewer B</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>Viewer C</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0</td></tr></table>

Discordant table:   

<table><tr><td rowspan=1 colspan=1>Viewer</td><td rowspan=1 colspan=1>Sample number</td><td rowspan=1 colspan=1>GC/MS result</td><td rowspan=1 colspan=1>viewer results</td></tr><tr><td rowspan=1 colspan=1>Viewer A</td><td rowspan=1 colspan=1>COCC1031</td><td rowspan=1 colspan=1>231</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>Viewer A</td><td rowspan=1 colspan=1>COCC1033</td><td rowspan=1 colspan=1>229</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>Viewer A</td><td rowspan=1 colspan=1>COCC1034</td><td rowspan=1 colspan=1>232</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>Viewer A</td><td rowspan=1 colspan=1>COCC1062</td><td rowspan=1 colspan=1>293</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>Viewer A</td><td rowspan=1 colspan=1>COCC1061</td><td rowspan=1 colspan=1>302</td><td rowspan=1 colspan=1>negative</td></tr><tr><td rowspan=1 colspan=1>Viewer A</td><td rowspan=1 colspan=1>COCC1064</td><td rowspan=1 colspan=1>314</td><td rowspan=1 colspan=1>negative</td></tr><tr><td rowspan=1 colspan=1>Viewer A</td><td rowspan=1 colspan=1>COCC1065</td><td rowspan=1 colspan=1>306</td><td rowspan=1 colspan=1>negative</td></tr><tr><td rowspan=1 colspan=1>Viewer A</td><td rowspan=1 colspan=1>COCC1091</td><td rowspan=1 colspan=1>351</td><td rowspan=1 colspan=1>negative</td></tr><tr><td rowspan=1 colspan=1>Viewer B</td><td rowspan=1 colspan=1>COCC1031</td><td rowspan=1 colspan=1>231</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>Viewer B</td><td rowspan=1 colspan=1>COCC1032</td><td rowspan=1 colspan=1>219</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>Viewer B</td><td rowspan=1 colspan=1>COCC1035</td><td rowspan=1 colspan=1>221</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>Viewer B</td><td rowspan=1 colspan=1>COCC1062</td><td rowspan=1 colspan=1>293</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>Viewer B</td><td rowspan=1 colspan=1>COCC1061</td><td rowspan=1 colspan=1>302</td><td rowspan=1 colspan=1>negative</td></tr><tr><td rowspan=1 colspan=1>Viewer B</td><td rowspan=1 colspan=1>COCC1063</td><td rowspan=1 colspan=1>325</td><td rowspan=1 colspan=1>negative</td></tr><tr><td rowspan=1 colspan=1>Viewer B</td><td rowspan=1 colspan=1>COCC1065</td><td rowspan=1 colspan=1>306</td><td rowspan=1 colspan=1>negative</td></tr><tr><td rowspan=1 colspan=1>Viewer C</td><td rowspan=1 colspan=1>COCC1032</td><td rowspan=1 colspan=1>219</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>Viewer C</td><td rowspan=1 colspan=1>COCC1033</td><td rowspan=1 colspan=1>229</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>Viewer C</td><td rowspan=1 colspan=1>COCC1034</td><td rowspan=1 colspan=1>232</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>Viewer C</td><td rowspan=1 colspan=1>COCC1062</td><td rowspan=1 colspan=1>293</td><td rowspan=1 colspan=1>positive</td></tr><tr><td rowspan=1 colspan=1>Viewer C</td><td rowspan=1 colspan=1>COCC1061</td><td rowspan=1 colspan=1>302</td><td rowspan=1 colspan=1>negative</td></tr><tr><td rowspan=1 colspan=1>Viewer C</td><td rowspan=1 colspan=1>COCC1063</td><td rowspan=1 colspan=1>325</td><td rowspan=1 colspan=1>negative</td></tr><tr><td rowspan=1 colspan=1>Viewer C</td><td rowspan=1 colspan=1>COCC1064</td><td rowspan=1 colspan=1>314</td><td rowspan=1 colspan=1>negative</td></tr><tr><td rowspan=1 colspan=1>Viewer C</td><td rowspan=1 colspan=1>COCC1065</td><td rowspan=1 colspan=1>306</td><td rowspan=1 colspan=1>negative</td></tr><tr><td rowspan=1 colspan=1>Viewer C</td><td rowspan=1 colspan=1>COCC1095</td><td rowspan=1 colspan=1>378</td><td rowspan=1 colspan=1>negative</td></tr></table>

Lay-user study

A lay user study was performed at three intended user sites with 260 lay persons, of which, 20 tested for drug-free samples, 120 for d-Amphetamine samples, 120 for benzoylecgonine samples. They had diverse educational and professional backgrounds and ranged in age from 21 to ${ > } 5 0$ years. Urine samples were prepared at the following concentrations; $- 1 0 0 \%$ $+ 1 - 7 5 \%$ $+ / - 5 0 \%$ , $+ 1 - 2 5 \%$ of the cut-off by spiking drug(s) into drug free-pooled urine specimens. The concentrations of the samples were confirmed by GC/MS. Each sample was aliquoted into individual containers, blind-labeled and randomized. Each participant was provided with the package insert, 1 blind labeled sample and a device. The results are summarized below:

<table><tr><td rowspan=1 colspan=2>Cup format</td><td rowspan=1 colspan=1>Number</td><td rowspan=1 colspan=2>OTC user</td><td rowspan=2 colspan=1>%AgreementWithGC/MS</td></tr><tr><td rowspan=1 colspan=1>Drug</td><td rowspan=1 colspan=1>Concentration</td><td rowspan=1 colspan=1>ofsamples</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Drug -free</td><td rowspan=1 colspan=1>-100%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=6 colspan=1>d-Amphetamine</td><td rowspan=1 colspan=1>-75%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-50%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-25%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>80%</td></tr><tr><td rowspan=1 colspan=1>+25%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>85%</td></tr><tr><td rowspan=1 colspan=1>÷50%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>+75%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=6 colspan=1>Benzoylecgonine</td><td rowspan=1 colspan=1>-75%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-50%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-25%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>85%</td></tr><tr><td rowspan=1 colspan=1>+25%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>80%</td></tr><tr><td rowspan=1 colspan=1>+50%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>+75%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>100%</td></tr></table>

Data analysis shows that all lay persons have carried out the test correctly and the results show good accuracy compared to theGC/MS. Also, a Flesch-Kincaid reading analysis was performed on both drug's package inserts (AMP and COC) and the score revealed a reading grade level of less than 7.

Clinical Studies Not applicable

# 11. Conclusion

Based on the test principle and performance characteristics of the device, it's concluded that $\mathbf { C } \mathbf { R } ^ { 3 }$ Keyless Split Sample Cup Amphetamine-Cocaine is substantially equivalent to the predicate.

GUANGZHOU WONDFO BIOTECH CO.. LTD. C/O JOE SHIA   
LSI INTERNATIONAL INC   
504 EAST DIAMOND AVE. SUITE F   
GAITHERSBURG MD 20878

Re: K141532 Trade/Device Name: CR² Keyless Split Sample Cup Amphetamine-Cocaine Regulation Number: 21 CFR 862.3100 Regulation Name: Amphetamine test system Regulatory Class: 11 Product Code: DKZ. DIO Dated: June 6, 2014 Received: June 10. 2014

Dear Mr. Shia:

We have reviewed your Section $5 1 0 ( k )$ premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28. 1976. the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device. subject to the general controls provisions of the Acl. The general controls provisions of the Act include requirements for annual registration. listing of devices. good manufacturing practice. labeling. and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (sec above) into either class I (Special Controls) or class ! (PMA). it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations. Title 21. Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements. including. but not limited to: registration and listing (21 CFR Part 807): labeling (21 CFR Parts 801 and 809): medical device reporting (reporting of medical device-related adverse events) (21 CFR 803): good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820): and if applicable. the electronic product radiation control provisions (Sections 531-542 of the Act): 21 CFR 1000- 1050.

Page 2-Mr. Shia

If you desire specific advice for your device on our labcling regulations (21 CFR Parts 801 and 89 please contact the Division f Industry and Consumer Education a its tolfree umber (800) 638 2041 or (301) 796-7100 or at its Internel address   
http://www.fda.gov/MedicalDevices/ResourcesforYou/ndustry/default.hum. Also. please notc the regulation entitled. "Misbranding by reference to premarket notification" (21 CFR Par .9For questins regarding theeporing verse events nder he R eulatin CFR Part 803). please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Offce of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education al its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address htp://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours.

# Courtney H. Lias -S

Courtney H. Lias, Ph.D.   
Director   
Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics   
and Radiological Health   
Center for Devices and Radiological Health

510(k) Number (if known) k141532

Device Name CR3 Keyless Split Sample Cup Amphetamine-Cocaine

Indications for Use (Describe)

CR3 Keyless Split Sample Cup Amphetamine-Cocaine is a rapid test or the qualitative detection  d-Amphetamine maormetaboliteAmphetamineand Benzoylecgonie maor metabolite Cocaine)inhuman urineat a cuto concentration of 1000ng/mL and 300ng/mL, respectively.

T  ve ulm eiv us yu eC ul  u u  u

For in vito diagnostic se only. It is intended or over-the-counler and for presciption ue

# Denise Johnson-lyles -S

This section applies only to requirements of the Paparwork Reduction Act of 1995.

'do not send your completed form to the pra staff email address below.\*

The burden time for this colection of infomation is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the colection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

\*An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

![](images/311f87285f5e859f4ffc841606633169ee313c0b4ed62844b1bfa22711c9cd93.jpg)